Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for ...
(NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today ...
OncoAssure Ltd, an Irish medical diagnostic company, announced the publication of new data in the journal BJUI Compass that demonstrate the clinical validation of OncoAssure Prostate, a novel biopsy ...
A hospital in Surrey says it is the first NHS trust in the UK to use a "revolutionary" new device that improves prostate cancer surgery and reduces the need for radiotherapy. The Histolog Scanner ...
Phase III trial presented at ASTRO in San Francisco finds five-treatment regimen poised to become new standard of care. SAN FRANCISCO, Sept. 29, 2025 /PRNewswire/ -- Men with intermediate-risk ...
A hydroablation device for benign prostatic hyperplasia showed promise as a potential treatment aid for early prostate cancer in a small Chinese study. The proportion of patients with detectable ...
ANN ARBOR, Mich. - Chuck Single and Jack Cochrane have plenty in common. They both are 76-year-old prostate cancer survivors, Ann Arbor residents and retired engineers determined to fix problems they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback